logo-loader

Genflow Biosciences files US patent for the use of Sirtuin-6 in liver disease

Published: 08:15 14 Dec 2022 GMT

Genflow Biosciences PLC -

Genflow Biosciences PLC (LSE:GENF), a biotech company developing gene therapies targeting the ageing process, has filed a new patent application with the US Patent and Trademark Office.

It relates to variants of Sirtuin-6, and the gene variant's therapeutic uses for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

The application was filed through Genflow's Belgian subsidiary, Genflow Biosciences SRL.

NAFLD affects around 20% of the general population, and the number of people with NASH is expected to rise due to growing obesity rates.

In the past decade, large drugmakers including Allergan (NYSE:AGN), Gilead, and Novartis have spent billions of dollars acquiring or licensing medicines designed to treat NASH.

"I'm proud of the tremendous progress Genflow has achieved in filing this new patent, and we look forward to adding to the expanding body of knowledge about ageing, and liver diseases, and bolstering our ever-growing patent portfolio," said Dr Eric Leire, chief executive of Genflow.

The international patent application for the use of SIRT6 in the treatment and prevention of age-related diseases has received its first positive review from the Patent Cooperation Treaty Examiner. The Examiner has confirmed the novelty and inventiveness of Genflow's filing, which represents the first significant step towards the patent being granted.

Genflow already holds an exclusive licence for this application.

Genflow Biosciences says new research grants validate its research into...

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire joins Proactive's Stephen Gunnion with details of two significant research grants in Belgium. The grants, aimed at fostering collaborations in advanced therapy medicinal products (ATMPs), notably support partnerships with EXO...

on 24/1/24